Clinical Trial Update: Rituximab for Idiopathic Nephrotic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial update for rituximab in idiopathic nephrotic syndrome completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Nephrotic Syndrome

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Istituto Giannina Gaslini | Conditions: Idiopathic Nephrotic Syndrome | Phase 3 | Status: COMPLETED